BRIEF-EMA Recommends Restricting Use Of Cancer Medicine Rubraca

BRIEF-EMA Recommends Restricting Use Of Cancer Medicine Rubraca
European Medicines Agency

European Medicines Agency:

* EMA: EMA RECOMMENDS RESTRICTING USE OF CANCER MEDICINE RUBRACA: 22/07/2022

* EMA - RECOMMENDATION DOES NOT AFFECT USE OF RUBRACA AS MAINTENANCE TREATMENT FOLLOWING CHEMOTHERAPY Source text for Eikon: Further company coverage:

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.